Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
Level 4 - case-series / case-control
Single-arm follow-up study / case series lacking a control group.
PubMed 33479501 · doi:10.1038/s41591-020-01206-4
What was done
Researchers evaluated the long-term clinical outcomes and circulating immune responses in 8 patients with surgically resected stage IIIB/C or IVM1a/b melanoma at a median of almost 4 years following treatment with NeoVax, a personalized long-peptide vaccine targeting up to 20 personal neoantigens per patient (NCT01970358).
What was found
At a median follow-up of almost 4 years, all 8 patients were alive, and 6 were without evidence of active disease. Neoantigen-specific T cells displaying a memory phenotype persisted long-term ex vivo. Neoantigen-specific T cell clones diversified over time into multiple T cell receptor clonotypes with distinct functional avidities. Investigators also detected tumor infiltration by neoantigen-specific T cell clones and observed epitope spreading after vaccination.
Why it matters
This study provides evidence that personalized neoantigen peptide vaccines can establish multi-year memory T cell responses and induce broader immune reactivity via epitope spreading in patients with resected high-risk melanoma.
Limits
The study is limited by an extremely small sample size (n = 8) and an uncontrolled, single-arm design, preventing definitive conclusions regarding the vaccine's direct contribution to clinical survival outcomes.